Natixis Advisors LLC Buys 5,259 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Key Points

• Natixis Advisors LLC increased its stake in Jazz Pharmaceuticals by 28.4% in the first quarter, now owning a total of 23,804 shares valued at approximately $2.96 million.
• Jazz Pharmaceuticals reported an EPS of ($8.25) for the last quarter, missing analyst estimates by ($2.64), despite a 2.1% increase in revenue year-over-year.
• Analysts have mixed outlooks for Jazz Pharmaceuticals, with a consensus price target of $181.43 and 13 "buy" ratings among equity research analysts.

Natixis Advisors LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 28.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,804 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,259 shares during the quarter. Natixis Advisors LLC's holdings in Jazz Pharmaceuticals were worth $2,956,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Arkadios Wealth Advisors grew its holdings in Jazz Pharmaceuticals by 118.7% during the 1st quarter. Arkadios Wealth Advisors now owns 12,710 shares of the specialty pharmaceutical company's stock valued at $1,578,000 after buying an additional 6,899 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $223,000. Vestcor Inc bought a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $601,000. XTX Topco Ltd purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth approximately $203,000. Finally, Hurley Capital LLC bought a new position in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on JAZZ shares. Royal Bank Of Canada decreased their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $181.43.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $0.78 during trading hours on Friday, hitting $111.30. 893,673 shares of the company's stock were exchanged, compared to its average volume of 971,168. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a market capitalization of $6.73 billion, a PE ratio of -16.54, a PEG ratio of 5.10 and a beta of 0.34. The business's 50 day simple moving average is $111.27 and its 200-day simple moving average is $117.53. The company has a current ratio of 1.62, a quick ratio of 2.97 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.30 EPS. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity

In other news, Director Seamus Mulligan purchased 1,621 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the acquisition, the director directly owned 101,621 shares of the company's stock, valued at $10,466,963. This represents a 1.62% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.